Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Boston Scientific Corp. (BSX) — XLV Health Care · S&P 500 Profile |波士頓科學公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Boston Scientific Corp. (BSX) — Business, History & S&P 500 Profile |波士頓科學公司介紹

Boston Scientific company profile · medical devices, MedSurg & Cardiovascular · history · financial snapshot · S&P 500 rank #202 · 波士頓科學公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 31, 2026
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$60.84B
Oct 31, 2026 (StockAnalysis)
S&P 500 WEIGHT
0.09%
Rank #202 · Oct 31, 2026 (Slickcharts)
FY2025 NET SALES
$20.07B
+19.9% YoY · gross profit $13.85B
FY2025 NET INCOME ATTRIBUTABLE
$2.90B
Diluted EPS $1.94 · operating income $3.61B

SNAPSHOT

TickerBSX (NYSE)
CompanyBoston Scientific Corp.
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#202 · 0.09% (Oct 31, 2026)
Sector rank#25 in Health Care (Oct 31, 2026)
HeadquartersMarlborough, Massachusetts
FoundedJune 29, 1979 (Watertown, Massachusetts; holding company to acquire Medi-Tech)
CEOMichael F. Mahoney (Chairman and Chief Executive Officer)
EmployeesApproximately 59,000 (FY2025 10-K)
Market cap$60.84B (Oct 31, 2026)
SEC filingsEDGAR — CIK 0000885725

WHAT IT DOES

Boston Scientific develops, manufactures and markets medical devices for interventional specialties — cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation — with the stated purpose of bringing more accessible, lower-cost, lower-trauma options to patients versus open surgery.

In the fourth quarter of 2025 the company reorganized into two reportable segments: MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular, combining the legacy Cardiology and Peripheral Interventions businesses. Cardiovascular is now two-thirds of sales, led by Electrophysiology net sales of $3,325M in 2025 (from $1,904M in 2024) and Watchman at $1,958M.

FY2025 net sales were $20,074M, up 19.9% from $16,747M, with gross profit of $13,854M and operating income of $3,613M. Research and development expense was $2,052M, about 10% of sales, funding the pipeline behind the electrophysiology and structural-heart growth.

BUSINESS SEGMENTS — FY2025 NET SALES

SegmentNet salesShareYoY
MedSurg$6.83B34.0%+13.2%
Cardiovascular$13.27B66.1%+22.4%
Foreign currency impact−$0.02B——
Total net sales (reported)$20.07B100%+19.9%
Source: Boston Scientific FY2025 Form 10-K segment note (year ended Dec 31, 2025). Reportable segment sales total $20,095M ($6,829M + $13,266M); a −$21M foreign currency impact reconciles to reported net sales of $20,074M. YoY is against FY2024 reportable segment sales (MedSurg $6,032M; Cardiovascular $10,840M).

HISTORY

YearMilestone
1979Boston Scientific founded June 29, 1979, as a holding company to acquire Medi-Tech, by John Abele and Peter Nicholas
2023Mandatory convertible preferred stock automatically converted to common stock (June 1, 2023)
2025Fourth-quarter reorganization combines legacy Cardiology and Peripheral Interventions into a single Cardiovascular segment
2025Net sales $20,074M (+19.9%); Electrophysiology $3,325M; diluted EPS $1.94

COMPETITIVE POSITION

  • Cardiovascular scale — Cardiovascular segment operating income was $4,303M (32.4% of segment sales) versus MedSurg $2,268M (33.2%), giving two profit engines rather than one.
  • Electrophysiology momentum — EP sales nearly doubled in two years ($800M in 2023 to $3,325M in 2025), the fastest-growing business unit in the portfolio.
  • R&D intensity — $2,052M of R&D in 2025 sustains new-product flow, but also means a failed trial or delayed approval directly hits the growth story.
  • Competition — Medtronic, Abbott and Johnson & Johnson MedTech contest the same cardiology, electrophysiology and endoscopy markets, often with larger scale.

FINANCIAL SNAPSHOT — FY2025

Net sales$20.07B (+19.9% YoY)
Gross profit$13.85B
Operating income$3.61B (vs $2.60B in FY2024)
Net income$2.89B
Net income attributable to common stockholders$2.90B
Diluted EPS$1.94 (vs $1.25 in FY2024)
Research and development$2.05B
Fiscal yearCalendar year (ended Dec 31, 2025)
Source: Boston Scientific FY2025 Form 10-K consolidated statements of operations (filed Feb 17, 2026). Figures are in millions in the filing and rounded here to two decimals in billions.

KEY RISKS

  • Litigation and product liability — the 10-K stresses that litigation-related charges are material and hard to predict; 2025 litigation-related net charges were $194M (versus a $111M credit in 2023).
  • Regulation — devices face FDA approval and EU Medical Device Regulation implementation costs; a delay or recall can stall a growth franchise.
  • Foreign currency — international net sales were $7,210M (35.9% of total) in 2025, so a stronger dollar mechanically shrinks reported growth.
  • Acquisition and goodwill — goodwill was $18,282M at Dec 31, 2025; acquired growth (notably in electrophysiology) must be integrated without impairment — 2025 intangible impairment charges were $46M, down from $386M in 2024.
  • Reimbursement and pricing — hospital budgets and payer coverage decisions govern adoption of premium devices; pricing pressure can offset volume growth.

WHY IT MATTERS FOR THE S&P 500

Boston Scientific is the S&P 500’s interventional-device compounder at a 0.09% weight and exactly #25 in Health Care by weight — the boundary of the sector top-25 — with growth now led by electrophysiology rather than its legacy cardiology base.

Its 2025 reorganization into MedSurg and Cardiovascular also simplifies how the index story reads: two segments, two margins, and one question — whether EP growth can sustain a $20B sales base without a new acquisition cycle.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 31, 2026 crawl) · StockAnalysis (market cap — Oct 31, 2026 crawl)
FinancialsBoston Scientific FY2025 Form 10-K (SEC EDGAR, filed Feb 17, 2026; fiscal year ended Dec 31, 2025)
Sector classificationGICS (Health Care Equipment) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Boston Scientific

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼BSX(NYSE)
公司Boston Scientific Corp.
GICS 板塊/行業醫療保健(XLV)/醫療保健設備
標普500排名(按權重)#202 · 0.09%(2026 年 10 月 31 日)
板塊內排名醫療保健第 #25(2026 年 10 月 31 日)
總部美國麻薩諸塞州馬爾伯勒
成立1979 年 6 月 29 日(麻薩諸塞州沃特敦;為收購 Medi-Tech 而設的控股公司)
行政總裁Michael F. Mahoney(董事長兼行政總裁)
員工約 59,000(FY2025 10-K)
市值$60.84B(2026 年 10 月 31 日)
SEC 申報EDGAR — CIK 0000885725

業務概覽

波士頓科學開發、製造及銷售介入專科醫療器械——心臟科、周邊介入、電生理、內窺鏡、泌尿科與神經調控——宗旨是較開刀手術提供更可及、更低成本、創傷更小的治療選擇。

2025 年第四季公司重組為兩個可報告板塊:MedSurg(內窺鏡、泌尿科、神經調控)與心血管,將原心臟科與周邊介入業務合併。心血管現佔銷售三分之二,其中電生理 2025 年淨銷售 $3,325M(2024 年為 $1,904M),Watchman 為 $1,958M。

FY2025 淨銷售 $20,074M,較 $16,747M 增長 19.9%,毛利 $13,854M,營業利潤 $3,613M。研發開支 $2,052M,約佔銷售 10%,為電生理與結構性心臟增長背後的產品線提供資金。

業務板塊 — FY2025 淨銷售

板塊淨銷售佔比同比
MedSurg$6.83B34.0%+13.2%
心血管$13.27B66.1%+22.4%
外匯影響−$0.02B——
淨銷售合計(已報告)$20.07B100%+19.9%
來源:Boston Scientific FY2025 Form 10-K 板塊附註(財政年度截至 2025 年 12 月 31 日)。可報告板塊銷售合計 $20,095M($6,829M + $13,266M),經 −$21M 外匯影響調整後為已報告淨銷售 $20,074M。同比對 FY2024 可報告板塊銷售(MedSurg $6,032M;心血管 $10,840M)。

歷史沿革

年份里程碑
1979Boston Scientific 於 1979 年 6 月 29 日成立,為收購 Medi-Tech 而設的控股公司,由 John Abele 與 Peter Nicholas 創立
2023強制可轉換優先股自動轉換為普通股(2023 年 6 月 1 日)
2025第四季重組,將原心臟科與周邊介入業務合併為單一心血管板塊
2025淨銷售 $20,074M(+19.9%);電生理 $3,325M;攤薄每股盈利 $1.94

競爭地位

  • 心血管規模——心血管板塊營業利潤 $4,303M(佔板塊銷售 32.4%),MedSurg 為 $2,268M(33.2%),形成雙盈利引擎。
  • 電生理動能——電生理銷售兩年內幾近翻倍(2023 年 $800M 至 2025 年 $3,325M),為組合中增長最快的業務單位。
  • 研發強度——2025 年研發 $2,052M,支撐新產品流,但試驗失敗或審批延遲會直接衝擊增長故事。
  • 競爭——Medtronic、Abbott 與 Johnson & Johnson MedTech 在同一心臟科、電生理與內窺鏡市場競爭,規模往往更大。

財務快照 — FY2025

淨銷售$20.07B(同比 +19.9%)
毛利$13.85B
營業利潤$3.61B(FY2024 為 $2.60B)
淨利潤$2.89B
歸屬普通股股東淨利潤$2.90B
攤薄每股盈利$1.94(FY2024 為 $1.25)
研發$2.05B
財政年度曆年(截至 2025 年 12 月 31 日)
來源:Boston Scientific FY2025 Form 10-K 合併利潤表(2026 年 2 月 17 日申報)。申報中金額以百萬美元計,此處四捨五入至十億美元兩位小數。

主要風險

  • 訴訟與產品責任——10-K 強調訴訟相關開支重大且難以預測;2025 年訴訟相關淨開支 $194M(2023 年為 $111M 抵免)。
  • 監管——器械須經 FDA 審批並承擔歐盟醫療器械法規實施成本;延遲或召回可拖慢增長業務。
  • 外匯——2025 年國際淨銷售 $7,210M(佔總額 35.9%),美元走強會機械地壓縮已報告增長。
  • 併購與商譽——2025 年 12 月 31 日商譽 $18,282M;併購增長(尤其電生理)須整合而不減值——2025 年無形資產減值 $46M,低於 2024 年的 $386M。
  • 報銷與定價——醫院預算與支付方覆蓋決定優質器械的採用;定價壓力可抵銷銷量增長。

對標普500的重要性

波士頓科學是標普500中的介入器械複合增長股:指數權重 0.09%、醫療保健權重恰為第 #25——板塊前 25 名的邊界——增長現由電生理而非傳統心臟科基盤帶動。

其 2025 年重組為 MedSurg 與心血管亦簡化了指數故事的讀法:兩個板塊、兩個利潤率,以及一個問題——電生理增長能否在不開啟新一輪併購週期的情況下支撐 $20B 銷售基數。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 31 日抓取)· StockAnalysis(市值——2026 年 10 月 31 日抓取)
財務Boston Scientific FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 17 日申報;財政年度截至 2025 年 12 月 31 日)
板塊分類GICS(醫療保健設備),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Boston Scientific

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · BSX
Data as of Oct 31, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Becton, Dickinson and Company (BDX) — XLV Health Care · S&P 500 Profile |碧迪介紹Next · Baker Hughes Company (BKR) — XLE Energy · S&P 500 Profile |貝克休斯介紹

Entered 2026-10-31 11:39 · updated 2026-11-14 23:05 · rev 6